Trending Stock News

Gagnon Securities Trimmed By $644,821 Its Christopher & Banks (CBK) Position; Antares Pharma (ATRS) Shorts Lowered By 51.21%

Gagnon Securities Llc decreased Christopher & Banks Corp (CBK) stake by 79.45% reported in 2017Q2 SEC filing. Gagnon Securities Llc sold 644,821 shares as Christopher & Banks Corp (CBK)’s stock declined 16.15%. The Gagnon Securities Llc holds 166,739 shares with $218,000 value, down from 811,560 last quarter. Christopher & Banks Corp now has $50.73M valuation. The stock increased 2.29% or $0.03 during the last trading session, reaching $1.34. About 131,930 shares traded. Christopher & Banks Corporation (NYSE:CBK) has declined 48.10% since December 1, 2016 and is downtrending. It has underperformed by 64.80% the S&P500.

Antares Pharma Incorporated (NASDAQ:ATRS) had a decrease of 51.21% in short interest. ATRS’s SI was 3.40M shares in December as released by FINRA. Its down 51.21% from 6.97 million shares previously. With 3.55 million avg volume, 1 days are for Antares Pharma Incorporated (NASDAQ:ATRS)’s short sellers to cover ATRS’s short positions. The SI to Antares Pharma Incorporated’s float is 2.91%. It closed at $1.85 lastly. It is down 207.14% since December 1, 2016 and is uptrending. It has outperformed by 190.44% the S&P500.

Since June 1, 2017, it had 3 buys, and 0 insider sales for $57,134 activity. Another trade for 30,000 shares valued at $40,663 was made by DUSKIN JONATHAN on Monday, June 12. The insider Stemper Cindy J bought $3,960.

Investors sentiment increased to 1.67 in Q2 2017. Its up 0.72, from 0.95 in 2017Q1. It improved, as 6 investors sold CBK shares while 9 reduced holdings. 8 funds opened positions while 17 raised stakes. 15.80 million shares or 6.44% less from 16.89 million shares in 2017Q1 were reported. Geode Mgmt Ltd Liability Co reported 200,064 shares or 0% of all its holdings. Gagnon Securities Limited Liability reported 166,739 shares or 0.06% of all its holdings. 77,314 were accumulated by Jpmorgan Chase. Palisade Asset Management Lc has 0.11% invested in Christopher & Banks Corporation (NYSE:CBK). Manufacturers Life Insur Co The has invested 0% in Christopher & Banks Corporation (NYSE:CBK). Heartland holds 750,000 shares. Accredited Invsts reported 40,900 shares. Awm Invest Incorporated reported 0.17% of its portfolio in Christopher & Banks Corporation (NYSE:CBK). Moreover, Vnbtrust Natl Association has 0.32% invested in Christopher & Banks Corporation (NYSE:CBK) for 612,109 shares. White Pine Cap Limited Liability Corp reported 1.20M shares stake. 92,787 are held by Luxor Capital L P. Tfs Cap Limited Co reported 0.01% of its portfolio in Christopher & Banks Corporation (NYSE:CBK). Vanguard Group Inc accumulated 750,744 shares or 0% of the stock. Gam Holdg Ag accumulated 75,000 shares. 88,177 are held by D E Shaw Com.

Among 2 analysts covering Christopher & Banks Corporation (NYSE:CBK), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Christopher & Banks Corporation had 5 analyst reports since August 14, 2015 according to SRatingsIntel. The stock of Christopher & Banks Corporation (NYSE:CBK) has “Buy” rating given on Wednesday, August 19 by Zacks. As per Monday, August 17, the company rating was downgraded by Dougherty & Company. The stock of Christopher & Banks Corporation (NYSE:CBK) earned “Buy” rating by Brean Capital on Friday, August 14. The firm has “Buy” rating by Dougherty & Company given on Friday, August 14. Dougherty & Company upgraded Christopher & Banks Corporation (NYSE:CBK) on Thursday, April 7 to “Buy” rating.

Investors sentiment decreased to 2.07 in Q2 2017. Its down 0.80, from 2.87 in 2017Q1. It dived, as 16 investors sold Antares Pharma, Inc. shares while 14 reduced holdings. 36 funds opened positions while 26 raised stakes. 53.64 million shares or 13.47% more from 47.27 million shares in 2017Q1 were reported. Credit Suisse Ag invested in 0% or 30,444 shares. State Common Retirement Fund stated it has 121,500 shares or 0% of all its holdings. Deutsche Retail Bank Ag reported 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Alliancebernstein L P holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 36,900 shares. Armistice Ltd Co owns 5.70 million shares or 2.34% of their US portfolio. Sii Incorporated Wi invested in 0% or 15,800 shares. State Board Of Administration Of Florida Retirement System stated it has 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Metropolitan Life Co Ny invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Invesco invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Morgan Stanley has 538,924 shares. California State Teachers Retirement System has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 254,600 shares. Jpmorgan Chase And Commerce reported 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Guggenheim Cap Limited Liability Corporation has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Perceptive Advsrs Limited Com holds 0.69% or 4.27 million shares in its portfolio. 89,132 are owned by Amer Intl.

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 10 analyst reports since March 9, 2016 according to SRatingsIntel. Jefferies maintained the shares of ATRS in report on Tuesday, October 10 with “Buy” rating. H.C. Wainwright initiated the stock with “Buy” rating in Friday, September 8 report. Jefferies maintained the stock with “Buy” rating in Wednesday, March 9 report. Jefferies maintained it with “Buy” rating and $600 target in Monday, August 7 report. The company was maintained on Monday, October 23 by Piper Jaffray. As per Monday, October 23, the company rating was maintained by H.C. Wainwright. On Wednesday, November 8 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Friday, June 23. Piper Jaffray maintained the shares of ATRS in report on Tuesday, July 25 with “Buy” rating.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $289.85 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *